Keystone Nano thinks its expertise in nanotechnology can be leveraged to achieve two valuable commercial goals: improving drug delivery and enhancing medical imaging. The company's Molecular Dots are particles that are just 20-30 nanometers wide and resist clumping. As such, they appear to be able to move through the body without disturbing the immune system.
158 Round Hill Road
Boalsburg, PA 16827
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The Italian drugmaker gets rights to Phase III-ready asset radiprodil.
New CEO Renée Aguiar-Lucander is marking her mark.
Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.
Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.
GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.
New CEO Renée Aguiar-Lucander is marking her mark.
Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.
